ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
13 Enero 2025 - 12:30AM
UK Regulatory
ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare
Conference
CEO Dave Marver to Provide Company Update Wednesday,
January 15, 2025
EINDHOVEN, the Netherlands, Jan. 13, 2025 (GLOBE
NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical
technology company creating innovative spinal cord stimulation
therapies to restore movement, function, and independence in people
with spinal cord injury (SCI) and other movement disabilities,
today announces that CEO Dave Marver will present a company update
at the 43rd Annual J.P. Morgan Healthcare Conference on
Wednesday, January 15 at 1:30pm Eastern Time (10:30am
Pacific Time / 7:30pm Central European Time).
The Company presentation and Q&A session will be webcast
live, and an archive recording will be available for 30 days. The
link to the live webcast and archive will be accessible on ONWARD
Medical’s investor website located at
https://ir.onwd.com/news-events
About ONWARD Medical
ONWARD Medical is a medical technology company creating
therapies to restore movement, function, and independence in people
with SCI and other movement disabilities. Building on more than a
decade of scientific discovery, preclinical research, and clinical
studies conducted at leading hospitals, rehabilitation clinics, and
neuroscience laboratories, the Company has developed ARC Therapy,
which has been awarded ten Breakthrough Device Designations from
the US Food and Drug Administration (FDA). In addition to the
ARC-EX System, which is now cleared for commercial sale in the US,
the Company is developing an implantable system called ARC-IM with
and without an implanted brain-computer interface (BCI).
Headquartered in the Netherlands, the Company has a Science and
Engineering Center in Switzerland and a US office in Boston,
Massachusetts. The Company is listed on Euronext Paris, Brussels,
and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com and connect with us on
LinkedIn and YouTube.
For Media Inquiries:
media@onwd.com
For Investor Inquiries:
Investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are
forward-looking, which reflect the Company’s or, as appropriate,
the Company directors’ current expectations and projections about
future events. By their nature, forward-looking statements involve
several risks, uncertainties, and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties, and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, delays in
regulatory approvals, changes in demand, competition, and
technology, can cause actual events, performance, or results to
differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, the Company expressly disclaims any obligation
or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions, or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
ARC-EX Indication for Use (US): The ARC-EX System is
intended to deliver programmed, transcutaneous electrical spinal
cord stimulation in conjunction with functional task practice
in the clinic to improve hand sensation and strength in
individuals between 18 and 75 years old that present with a
chronic, non-progressive neurological deficit resulting from an
incomplete spinal cord injury (C2-C8 inclusive).
Other Investigational Products: All other ONWARD Medical
devices and therapies including ARC-IM and ARC-BCI are
investigational and not available for commercial use.
Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the
stylized O-Logo are proprietary and registered trademarks of ONWARD
Medical. Unauthorized use is strictly prohibited.
Onward Medical NV (EU:ONWD)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Onward Medical NV (EU:ONWD)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
